| 货号 | BAF2460 |
| 别名 | coagulation factor XI; EC 3.4.21; EC 3.4.21.27; FXIPlasma thromboplastin antecedent; MGC141891; PTA |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) |
| 目标/特异性 | Detects human Coagulation Factor XI in Western blots. In Western blots, approximately 20% cross-reactivity with recombinant mouse Coagulation Factor XI is observed and less than 1% cross-reactivity with recombinant human Coagulation Factor VII and recominbnat human Coagulation Factor X is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL |
| 来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 2160 (Human); 109821 (Mouse) |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human Coagulation Factor XI Glu19-Val625 Accession # P03951 |
| 生物活性 | Human |
| 标记 | Biotin |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Coagulation Factor XI is synthesized in the liver and circulates in the plasma as a disulfide bond-linked dimer complexed with High Molecular Weight Kininogen. Factor XI is converted into active XIa either via the contact phase of blood coagulation or through Thrombin-mediated activation on the platelet surface. The resulting XIa converts Coagulation Factor IX into IXa, which subsequently activates Coagulation Factor X (Xa). Xa then can mediate Coagulation Factor II/Thrombin activation. Patients with factor XI deficiency are prone to excessive bleeding after hemostatic challenge. |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 参考文献 |
|